Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vistagen Therapeutics (VTGN) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$18.9 million.

  • Vistagen Therapeutics' Net Income towards Common Stockholders fell 3414.01% to -$18.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$67.0 million, marking a year-over-year decrease of 4173.43%. This contributed to the annual value of -$51.4 million for FY2025, which is 7511.75% down from last year.
  • Per Vistagen Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$18.9 million for Q4 2025, which was down 3414.01% from -$19.4 million recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Net Income towards Common Stockholders registered a high of -$6.4 million during Q4 2023, and its lowest value of -$29.6 million during Q1 2021.
  • For the 5-year period, Vistagen Therapeutics' Net Income towards Common Stockholders averaged around -$13.6 million, with its median value being -$13.1 million (2021).
  • In the last 5 years, Vistagen Therapeutics' Net Income towards Common Stockholders plummeted by 72271.08% in 2021 and then surged by 6509.46% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$10.7 million in 2021, then rose by 9.13% to -$9.8 million in 2022, then surged by 34.95% to -$6.4 million in 2023, then crashed by 121.87% to -$14.1 million in 2024, then tumbled by 34.14% to -$18.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$18.9 million for Q4 2025, versus -$19.4 million for Q3 2025 and -$15.1 million for Q2 2025.